Ana Belén Crujeiras
Awardee of the Clinic category
Group Leader at the Instituto de Investigaciones Sanitarias de Santiago and the Servicio Gallego de Salud (IDIS-SERGAS)
Obesity is expected to become the leading preventable cause of cancer in the coming years. In the case of breast cancer—the most common cancer among women and the second leading cause of female mortality—obesity not only increases the risk of developing the disease but also raises the likelihood of relapse after treatment, complicating recovery and accelerating aging in survivors.
Although it is well established that obesity worsens prognosis, there are still no clinical studies evaluating whether weight loss actually improves the effectiveness of cancer treatments. Crujeiras’ project aims to generate this evidence for the first time. The study will involve postmenopausal women with obesity, with and without breast cancer, who will follow either a low-calorie ketogenic diet—a very low-carbohydrate, moderate-protein, and healthy-fat dietary pattern—or a Mediterranean-based nutritional intervention for weight loss, comparing outcomes with groups of women of healthy weight.
Supported by the Jesús Serra Research Award, this project will help improve oncological treatments by integrating nutritional therapies into clinical care, advance personalized medicine, and promote preventive and sustainable strategies to reduce the health and social impact of obesity.
About Ana Belén Crujeiras: She holds a degree in Biology from the University of Santiago de Compostela (USC) and a PhD in Physiology and Nutrition from the University of Navarra (UNAV). She leads the Epigenomics in Endocrinology and Nutrition group at the Health Research Institute of Santiago (IDIS) and at CIBER in Obesity and Nutrition Pathophysiology (CIBERobn), and she is a professor in the Endocrinology doctoral program at USC. Her research focuses on how diet and nutritional status influence health through epigenetic mechanisms, with a special interest in obesity and its comorbidities, including cancer. She is an associate editor and member of several editorial boards, serves on the board of the Spanish Society of Obesity (SEEDO), and participates in scientific advisory programs and public health initiatives.
Jordi Mayners - Perxachs
Awardee of the Basic category
Group Leader at the Institut d’Investigació Biomèdica de Girona (IDIBGI)
Obesity affects more than 890 million people worldwide. Among the factors contributing to this epidemic, food addiction stands out—a disorder affecting approximately 20% of the population, characterized by compulsive consumption of highly caloric foods rich in sugar, fat, or salt. Although it shares many behavioral, brain, and neuropsychological mechanisms with substance addictions, there are currently no effective treatments for addressing it.
The gut microbiota appears to play a key role in appetite regulation, but its relationship with food addiction is still poorly understood. Jordi Mayneris Perxachs’ project investigates how a common gut bacterium—which also acts as a natural probiotic—and the compounds it produces could prevent or treat this addiction. To this end, he combines studies in humans and animal models to understand how the microbiota influences the brain and compulsive behaviors. With the Jesús Serra Research Award, the goal is to identify the key mechanisms linking the microbiota and food addiction, paving the way for new natural interventions to help prevent and treat this disorder, offering an innovative approach to obesity and its health consequences.
About Jordi Mayneris-Perxachs: He holds a PhD in Computational Chemistry from the University of Barcelona (UB) and specialized in Systems Biology and Omics Sciences during postdoctoral stays at the Universities of Reading and Imperial College London. After leading projects at EURECAT on polyphenols and metabolic health, he joined the Institute for Biomedical Research of Girona (IDIBGI) in 2019, focusing his research on microbiota-brain communication in obesity, cognitive function, and depression. Since 2024, he has led the Integrative Systems Medicine and Biology group at IDIBGI, exploring connections between the microbiome, food addiction, cognition, and mental and metabolic health, with high-impact publications, six patents, and national and international recognition. Since 2021, he has also been part of CIBER in the areas of Obesity and Nutrition Pathophysiology (CIBEROBN).
Andreea Ciudin
Winner of the Clinical category
Principal Investigator at the Vall d'Hebron Research Institute (VHIR) and Coordinator of the Comprehensive Obesity Treatment Unit at the Vall d'Hebron University Hospital.
One in eight people suffers from obesity, a chronic and recurrent disease characterised by an excess of body fat that is harmful to our health. For a long time, this disease has been classified based on body mass index (BMI). However, BMI does not take into account factors such as body composition, fat accumulation in the liver, or resting energy expenditure, which are key to identifying the best therapeutic strategy and understanding long-term treatment response.
Andreea Ciudin and her team have developed and validated a software in individuals with obesity that allows for precise evaluation of body composition and resting energy expenditure using computed tomography (CT) images, with results superior to other diagnostic methods. With the Jesús Serra Research Awards, Ciudin aims to take this a step further by identifying different obesity patterns through the extraction of information using artificial intelligence (AI) and CT images. This will allow for the development of personalised nutritional approaches and therapies that improve therapeutic outcomes and prevent the onset of comorbidities.
About Andreea Ciudin: After completing her medical residency in Endocrinology and Nutrition, Andreea Ciudin earned her PhD in Medicine from the Autonomous University of Barcelona. She is currently the coordinator of the Comprehensive Obesity Treatment Unit at the Vall d'Hebron University Hospital and the principal investigator of the Diabetes and Metabolism research group at VHIR. Additionally, she is an associate professor at the Autonomous University of Barcelona, a member of the Spanish Society for the Study of Obesity (SEEDO), and co-chair of the Obesity Management Working Group of the European Association for the Study of Obesity (EASO).
María Mittelbrunn
Winner of the Basic category
Senior Scientist at the Consejo Superior de Investigaciones Científicas (CSIC) and Laboratory Director at the Severo Ochoa Molecular Biology Center (CSIC-UAM).
Our immune system protects us from infections, pathogens and diseases like cancer. However, as we age, it weakens and becomes less effective. This process, known as immunosenescence, also leads to a state of chronic inflammation in the body, increasing the risk of age-related diseases such as cardiovascular or neurodegenerative conditions.
María Mittelbrunn and her team study how to delay this immunosenescence, specifically the metabolic deterioration of T lymphocytes, through combinations of diets and pharmacological compounds. With the Jesús Serra Research Awards, Mittelbrunn will analyse new nutritional strategies in animal models that could improve the metabolism of T lymphocytes, thereby rejuvenating the immune system, controlling chronic inflammation and promoting healthy ageing.
About María Mittelbrunn: After earning her PhD in Biomedicine, Biochemistry and Molecular Biology from the Autonomous University of Madrid, she worked as a postdoctoral researcher at the National Center for Cardiovascular Research (CNIC), the University of Oviedo and the Curie Institute in Paris, as well as a principal investigator at the 12 de Octubre Hospital. She currently leads the Laboratory of Immunometabolism and Inflammation at the Severo Ochoa Molecular Biology Center (CBM) in Madrid and is a Senior Scientist at CSIC.
Maira Bes Restrollo
Clinical Research
Professor of Preventive Medicine and Public Health at the University of Navarra (UNAV).Maira Bes is one of Spain’s leading health science researchers in the area of Nutrition and Dietetics and one of the best Spanish scientists according to the ranking established by the CSIC. Her research into nutritional epidemiology focuses on understanding how different diet patterns have an effect on chronic diseases and mortality, given that these diseases are the main cause of death worldwide and are partly the result of poor nutrition.
Sustainable Development Goal SDG3, Good Health and Well-being, emphasises the need to promote a diet that is primarily plant-based and which, in addition to being healthy, is more environmentally sustainable. However, diets of this type can be nutritionally deficient, and their nutritional quality varies according to food options.
Thanks to the support provided by the Fundación Occident Research Awards, Maira Bes will develop and validate the world’s first survey to assess the nutritional quality of vegan diets on a standardised basis. This will make it possible to detect dietary and health risks in a clinical context and will help health professionals improve dietary recommendations for vegans.
About Maira Bes: After obtaining a PhD in Pharmacy from the UNAV, Bes completed a post-doctoral stay at Harvard University and was a visiting researcher at the University of Loma Linda. She is currently the Lead Researcher of the SUN Project and the Diet and Lifestyles group at the Health Research Institute of Navarra (IdiSNA), a research affiliate with CIBERobn, and the coordinator of the Spanish Society of Epidemiology’s Nutrition work group. In addition, she combines her research work with teaching the degrees of Medicine, Pharmacy and Nutrition at UNAV.
Manuel Irimia
Basic Research
ICREA research professor and group leader at the Centre for Genomic Regulation (CRG) in Barcelona.
Diabetes is a disease that affects almost 10% of the world’s adult population, with an increasing prevalence worldwide. This life-threatening illness, which poses a major challenge for healthcare systems, is characterised by the poor functioning or loss of beta cells. These cells are characteristic of a series of structures in the pancreas known as “islets of Langerhans”, which are responsible for producing insulin, the hormone responsible for maintaining glycaemic blood control. However, the mechanisms underlying the failure of these cells in diabetes are not well known, and there are still no effective interventions to prevent it.
In a recent study published in Nature Metabolism, Irimia’s team discovered that microexons play a key role in the function of the pancreas and glycaemic regulation. Therefore, they are a possible therapeutic target for treating diabetes. Microexons are minute fragments of DNA that are part of more than 100 genes, including vital genes for insulin secretion. With the project that has received the Fundación Occident Award, Irimia and his team want to explore their use in defining new molecular targets and therapeutic strategies for diabetes, thus contributing to reducing the disease’s comorbidity and the burden on healthcare systems.
About Manuel Irimia: Irimia obtained a PhD in Genetics from the University of Barcelona and completed post-doctoral stays at the University of Stanford and the University of Toronto. On his return, in 2014, he joined the Centre for Genomic Regulation (CRG), where he has since led the research group “Transcriptomics of vertebrate development and evolution”.
Fátima Crispi
Clinical Research
Senior specialist in the Foetal Cardiology Unit of the Centre for Maternal-Foetal Medicine at Hospital Clínic de Barcelona and the Hospital Sant Joan de Déu, where she leads a pioneering consultation for the study of the foetal heart in extra-cardiac pathologies. Crispi combines her healthcare work with her work as a researcher at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and at BCNatal. She is also an associate professor at the University of Barcelona.
Her research has focused on studying babies born with a low weight, a condition that affects 7-10% of newborns and that has no treatment. This condition is associated with a high perinatal morbi-mortality, and also has consequences on the cardiovascular health of these future children and adults.
Crispi described how the heart of these foetuses is remodelled to adapt to the placental insufficiency that causes the low weight and, subsequently, she demonstrated that these cardiovascular changes persisted in childhood, adolescence and adulthood, which probably explains their greater susceptibility to cardiovascular diseases.
Following a study involving the diet of pregnant women, Crispi and her team were able to reduce by 30% the number of babies with a low birthweight, as well as the associated cardiovascular damage. Thanks to the support of the Fundación Jesús Serra, her objective is now to study whether benefits on cardiovascular development persist in children a few years after their birth.
Arkaitz Carracedo
Basic Research
Ikerbasque Research Professor at the Centre for Cooperative Research in Biosciences (CIC bioGUNE) and Associate Professor at the University of the Basque Country. Arkaitz Carracedo received a PhD in Biochemistry and Molecular Biology from the Complutense University of Madrid. After postdoctoral positions at the Memorial Sloan-Kettering Cancer Center Hospital and Beth Israel Deaconess Medical Center, Harvard Medical School (USA), he established his research group at CIC bioGUNE at the end of 2010. His laboratory is a pioneer in the study of the metabolic bases of prostate cancer. His research in this field has been funded by three projects of the European Research Council (ERC) and has also been recognised with numerous awards, to which he now adds the Fundación Jesús Serra Research Award.
Prostate cancer is the most common among men, which is a major health and socio-economic problem. The winning project aims to understand the molecular bases that regulate the aggressiveness of this type of cancer.Specifically, Carracedo aims to clarify the molecular effects of polyamines on tumour and non-tumour cells, and thus define their therapeutic potential to regulate their synthesis in our organism or even refine their use as dietary supplements.
Polyamines are key molecules in cell growth, development and senescence. These molecules are found easily in the Mediterranean diet and are postulated as healthy dietary supplements due to their anti-inflammatory and anti-ageing effects. However, Carracedo and his team have discovered that the metabolism of polyamines is altered in cancer cells, generating higher concentrations of this molecule that could determine the progress of prostate cancer. A better understanding of this crossover effect of polyamines will allow therapeutic interventions to be developed that find a balance between their healthy effects and the access of cancer cells to these molecules.
whose prevalence is steadily increasing and for which there is no treatment.
Mª. Carmen Collado
Clinical Research (ex aequo)
Agricultural Engineer (2000) and Graduate in Food Science and Technology (2002) from the Polytechnic University of Valencia (UPV). In January 2005, she completed a PhD from the UPV and won the Extraordinary PhD Prize.
Currently, she is Scientific Research Fellow of the CSIC in the Group of Tactical and Probiotic Bacteria at the Institute of Agrochemistry and Food Technology (IATA-CSIC). Since 2007 she has been an assistant professor at the University of Turku (Finland). Dr. Collado also participates in various specialisation courses, including on Master’s degrees at the UPV, University of Valencia (UV) and University of Turku (Finland).
Her research is framed by the establishment of associations between human microbiota, food and health in the maternal and child binomial. More specifically, her team investigates the impacts of early exposure (perinatal, environmental and genetic factors) on the microbiota as well as components specific to breast milk (including immune markers, metabolites, oligosaccharides, microbiota), and the impacts of these on the health of the child and the future adult.
Borja Ibáñez
Clinical Research (ex aequo)
A cardiologist at the Hospital Fundación Jiménez Díaz in Madrid, and group leader at CIBER on cardiovascular diseases (CIBERCV), he is a world opinion leader in the field of heart disease. He has been chosen by the European Cardiology Society as the chairman of the clinical practice guides for the treatment of acute myocardial infarction. His speciality is “Anthracycline cardiotoxicity: development of therapies aimed at mitochondrial protection. From mechanism to the patient.”
He has published more than 240 scientific articles, half of them as lead author, in top journals such as Science, The Lancet, JACC, European Heart Journal, Nature Communications, among others.
Dr. Ibáñez leads research in the field of myocardial diseases, in particular acute myocardial infarction, heart failure, and cardiotoxicity associated with cancer treatments.
In this regard, one of his lines of research is to develop a new therapeutic intervention aimed at reducing the prevalence of chronic heart failure in cancer survivors. A clinical trial is currently underway to this end, in which a new bioimaging marker will be validated that can identify very early stages of heart damage in patients undergoing anticancer therapy.
He is also the principal investigator of a major international clinical trial (REBOOT, with 8,500 post-infarction patients) that will change treatment guidelines for this condition around the world. His most recent research includes leadership of a clinical trial in 7 European countries testing this therapy in lymphoma patients (RESILIENCE).
Recent awards Dr Ibáñez has received include the ‘Young Talent’ Award at the 6th edition of the Constantes y Vitales Biomedical Research Awards, the Prince of Girona Award, the FPdGi Scientific Research Award, and the Banco Sabadell Foundation Award for Biomedical Research.
Rubén Nogueiras
Basic Research
Professor and researcher on the Oportunius Programme at the Singular Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS) of the University of Santiago de Compostela, where he coordinates the Molecular Metabolism group.
His career has always focused on the study of molecular mechanisms involved in obesity, a pandemic disease with a particularly high economic, social and health cost. The main lines of research of his group include:
- Investigating the mechanisms involved in the interaction between the central nervous system and peripheral organs to regulate energy balance. This has led to the identification of various factors involved in this interaction, including several gastrointestinal hormones, melanin-concentrating hormone, dopamine and the p53 gene.
- His team has recently been working to identify new mechanisms involved in the development of non-alcoholic fatty liver disease, a disease closely linked to obesity whose prevalence is steadily increasing and for which there is no treatment.
Raúl Zamora
Clinical Research
Private foundation of the Bellvitge Biomedical Research Institute and of the Catalan Institute of Oncology
Raúl Zamora Ros is part of the team of researchers from the private foundation Bellvitge Biomedical Research institute (IDIBELL). He received this award for his research work in the field of clinical research, and in particular for his research work “Dietary polyphenols and their effects on obesity markers”, which assesses the association between exposure to polyphenols and obesity markers, as well as their effect on health parameters and weight loss during a slimming treatment.
Salvador Aznar
Basic Research
Catalan Institute of Research and Advanced Studies (ICREA) and Biomedical Research Institute of Barcelona (IRB Barcelona)
Salvador Aznar Benitah, from the Catalan Institute of Research and Advanced Studies (ICREA) and the Biomedical Research Institute of Barcelona (IRB Barcelona), was chosen for his extensive work in the field of basic research, and in particular for his research on the “Impact of dietary fatty acids on metastasis-initiating cells”. This project aims to delve into recent discoveries on metastasis-initiating cells with high levels of the fatty acid receptor CD36. The research team hopes to obtain essential information on the mechanisms of metastasis and how they are influenced by diet. This point is important since Western diets have a large intake of fatty acids, and metastasis is the leading cause of cancer-related deaths.
Dra. Guadalupe Sabio
Basic Research
Scientist and professor, she holds a Bachelor’s Degree in Veterinary Medicine from the University of Extremadura with an Extraordinary Prize (2000) and a PhD from the Medical Research Council.
She worked as a research associate at the Faculty of Medicine, University of Massachusetts (Worcester, United States), until 2009 when she returned to Spain under a Ramón y Cajal contract to study diseases associated with obesity, such as diabetes, cardiovascular diseases and cancer. In 2011 she joined the CNIC, where she leads the research group on this subject. In 2018 she received the Fundación Jesús Serra Research Award for her professional career, presenting a project on the role of mitogen-activated protein kinases in regulating the signalling pathways involved in metabolism, cell proliferation, differentiation and apoptosis.
Dr. Pablo Pérez
Clinical Research
Degree in Medicine and Surgery from the University of Córdoba (1997), specialist in Internal Medicine at the Reina Sofía University Hospital.
Professor of Medicine at the University of Cordoba, he is currently working as a principal investigator at the Maimonides Institute for Biomedical Research. His scientific activity has focused on the study of clinical nutrigenomics, focusing on gene-environment interaction, including intestinal microbioma and somatic genomes, biomodulation of cardiovascular disease, and diabetes. He won the Fundación Jesús Serra Research Award for his professional career with a project on the role of the Mediterranean diet in improving mild cognitive impairment through the modulation of neuropeptides, fatty acids, markers of oxidative stress and inflammation in the microbiota, intestine and brain.
